Key result
Empagliflozin treatment significantly decreased the mean frontal plane QRS-T angle from 62° at baseline to 50.5° at 6 months (p < 0.001), an effect observed only in patients with known CVD.
Why the study?
Empagliflozin reduces cardiovascular events in diabetes mellitus, but little is known about its effect on electrocardiography parameters such as the frontal plane QRS-T angle.
Does empagliflozin improve the frontal plane QRS-T angle in patients with type 2 diabetes mellitus?
Cohort (n=111)
Does empagliflozin improve the frontal plane QRS-T angle in patients with type 2 diabetes mellitus?
Empagliflozin significantly narrows the frontal plane QRS-T angle, a marker of ventricular repolarization heterogeneity, in type 2 diabetes patients with established cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for QRS-T angle as SGLT2i marker in CVD; leaves open prognostic relevance and practice implications.
WHAT IS KNOWN AND OBJECTIVE: Empagliflozin treatment is significantly associated with lower risk of cardiovascular events in patients with diabetes mellitus (DM) independent of its antihyperglycemic effect. However, little is known regarding the impact of empagliflozin on electrocardiography (ECG) parameters. This study aimed to investigate whether empagliflozin has favourable effect on frontal plane QRS-T (fQRST) angle, which is an ECG sign of ventricular repolarization heterogeneity, in patients with type 2 DM. METHODS: We prospectively enrolled 111 patients with known diagnosis of type 2 DM who newly prescribed empagliflozin on top of their standard anti-diabetic therapy. Patients were divided into two groups according to presence or absence of cardiovascular disease (CVD) at baseline and followed-up for 6 months. The impact of empagliflozin treatment on fQRST angle was investigated and patient groups were compared regarding the pre- and post-treatment fQRST angle. RESULTS AND DISCUSSION: Among 111 patients, 32 (28.8%) had CVD and 79 (71.2%) had no CVD. Empagliflozin treatment lead a significant decrease in the mean fQRST angle throughout the study period and mean fQRST angle was significantly lower at 3- and 6-month follow-up visits compared to baseline values (62° ± 17.4° vs. 57.2° ± 14.8° vs. 50.5° ± 13.6°, p < 0.001 for all dual comparisons). However, despite similar antihyperglycemic effect with empagliflozin treatment in patients with and without CVD, the significant decrease in the mean fQRST angle was observed only in patients with CVD and no significant decrease was observed in the mean fQRST angle in patients without CVD. WHAT IS NEW AND CONCLUSION: Empagliflozin leads a significant narrowing in the fQRST angle in type 2 DM patients with known CVD.
No takes yet. Share an insight, caveat, or question.
Eyüboğlu et al. (2022) conducted a cohort in Type 2 diabetes mellitus (n=111). Empagliflozin vs. Baseline was evaluated on Mean frontal plane QRS-T (fQRST) angle (p=<0.001). Empagliflozin treatment significantly decreased the mean frontal plane QRS-T angle from 62° at baseline to 50.5° at 6 months (p < 0.001), an effect observed only in patients with known CVD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: